Robert F. Kennedy Jr. clinched the political support needed to become the nation's top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.
The Food and Drug Administration will soon "unleash a massive framework" for how vaccines are tested and approved, according to Commissioner Marty Makary . Details aren't yet public but the plan is being overseen by the agency's new vaccine chief, Dr. Vinay Prasad , an outspoken critic of FDA's handling of COVID-19 boosters.
Makary and other Trump administration officials already have taken unprecedented steps that raise uncertainty about next fall's COVID-19 vaccinations, including delaying FDA scientists' full approval of Novavax's shot - and then restricting its use to people at higher risk from the virus. They've also suggested seasonal tweaks to match the latest circulating virus strains are new products requiring extra testing.
The changes cross multiple health agencies.
The Centers for Disease Control and Prevention hasn't yet acted on an influential advisory panel's recent recommendations on use of a new meningitis shot or broader RSV vaccination. A meeting of Kennedy's "Make America Healthy Again" allies was recently told to expect an end to COVID-19 booster recommendations for children - something that vaccine advisory panel was supposed to debate in June. And researchers around the country lost National Institutes of Health funding to study vaccine hesitancy.